de la Rubia A - Search Results

1

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

LLerena A, de la Rubia A, Berecz R, Dorado P. LLerena A, et al. Among authors: de la rubia a. Pharmacopsychiatry. 2004 Mar;37(2):69-73. doi: 10.1055/s-2004-815528. Pharmacopsychiatry. 2004. PMID: 15048614

2

QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

LLerena A, Berecz R, de la Rubia A, Dorado P. LLerena A, et al. Among authors: de la rubia a. Eur J Clin Pharmacol. 2002 Jun;58(3):223-24. doi: 10.1007/s00228-002-0452-7. Eur J Clin Pharmacol. 2002. PMID: 12162273 Clinical Trial. No abstract available.

3

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.

LLerena A, Berecz R, de la Rubia A, Dorado P. LLerena A, et al. Among authors: de la rubia a. J Psychopharmacol. 2002 Dec;16(4):361-4. doi: 10.1177/026988110201600411. J Psychopharmacol. 2002. PMID: 12503836 Clinical Trial.

4

Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.

Peñas-Lledó EM, Dorado P, Cáceres MC, de la Rubia A, Llerena A. Peñas-Lledó EM, et al. Among authors: de la rubia a. Clin Chem Lab Med. 2007;45(7):835-8. doi: 10.1515/CCLM.2007.181. Clin Chem Lab Med. 2007. PMID: 17617023

5

Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.

Dorado P, Peñas-LLedó EM, de la Rubia A, LLerena A. Dorado P, et al. Among authors: de la rubia a. Pharmacogenomics. 2009 Jul;10(7):1083-9. doi: 10.2217/pgs.09.57. Pharmacogenomics. 2009. PMID: 19604081

6

High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.

Dorado P, de Andrés F, Naranjo ME, Peñas-Lledó EM, González I, González AP, de la Rubia A, Llerena A. Dorado P, et al. Among authors: de la rubia a, de andres f. Drug Metabol Drug Interact. 2012;27(3):165-70. doi: 10.1515/dmdi-2012-0016. Drug Metabol Drug Interact. 2012. PMID: 23089607 Clinical Trial.

7

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

Llerena A, Berecz R, Dorado P, de la Rubia A. Llerena A, et al. Among authors: de la rubia a. J Psychopharmacol. 2004 Jun;18(2):189-93. doi: 10.1177/0269881104042618. J Psychopharmacol. 2004. PMID: 15260906

8

Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.

LLerena A, Dorado P, Berecz R, González A, Jesús Norberto M, de la Rubia A, Cáceres M. LLerena A, et al. Among authors: de la rubia a. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):25-31. doi: 10.1016/s1570-0232(02)00486-5. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12450521

9

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Berecz R, et al. Among authors: de la rubia a. Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28. Eur J Clin Pharmacol. 2003. PMID: 12682803 Clinical Trial.

10

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.

Berecz R, LLerena A, de la Rubia A, Gómez J, Kellermann M, Dorado P, Degrell I. Berecz R, et al. Among authors: de la rubia a. Pharmacopsychiatry. 2002 Nov;35(6):231-4. doi: 10.1055/s-2002-36389. Pharmacopsychiatry. 2002. PMID: 12518271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results